

中国新药杂志

半月刊

第 20 卷第 17 期
2011 年 9 月 15 日

刊名题写：桑国卫

目次

- 卷首语 孙燕 (1587)
- **特别关注**
- 进一步提高中西医结合防治肿瘤的临床研究水平 孙燕 (1588)
- **世界新药之窗** (1592)
- **新药述评**
- EGFR-TKIs 治疗非小细胞肺癌进展 谭芬来, 王印祥, 袁晓盼等 (1594)
- 治疗肺癌新药 crizotinib 的药理作用和临床研究进展 王燕, 于舒飞 (1602)
- **新药研发论坛**
- 创新药物临床试验中暴露量-效应关系研究的探讨 魏敏吉, 赵明, 单爱莲 (1608)
- 我国药物临床试验法规与相关国际法规的对比研究 闫永波, 李野 (1612)
- **新药申报与审评技术**
- 我国小分子靶向抗肿瘤药物申报现状浅析 陈晓媛, 张虹, 高晨燕等 (1615)
- **重大新药创制专项巡礼**
- T 细胞依赖性抗体反应检测方法研究进展 霍艳, 艾文超, 苗玉发等 (1620)
- 星点设计-效应面法优化去甲斑蝥素壳聚糖-丝素蛋白栓塞微球的制备
..... 张光宇, 迟美玉, 倪静等 (1624)
- 乳糖化-去甲斑蝥素磷脂复合物及其 pH 敏感型脂质体的制备 周奕, 许静玉, 管敏等 (1631)
- **综述**
- 中医药与肿瘤——历史的积淀与五十年的创新发展 林洪生, 张英 (1639)
- 2011 年晚期非小细胞肺癌诊疗规范中药物应用解读 邢锴元, 石远凯 (1643)
- 2011 年版中国《肾细胞癌诊治指南》药物治疗原则解读 寿建忠, 马建辉 (1647)

伊马替尼治疗失败慢性期 CML 患者及早干预的意义及二代 TKIs 选择	周励 (1652)
胃肠间质瘤伊马替尼辅助治疗新进展	蒋伟忠 (1657)
酪氨酸激酶抑制剂类新药的研究现状	周冰莹, 安春娜, 蒲小平 (1661)
基于靶蛋白结构的 CDK2 小分子抑制剂研究进展	白晓光, 许乐幸, 李伟亮等 (1667)

■ 临床研究

FOLFOLX 4 方案治疗晚期肝细胞癌的多中心 II 期临床研究	龚新雷, 秦叔逵, 王雅杰等 (1673)
苹果酸法米替尼 I 期临床人体耐受性研究初步总结	周爱萍, 张雯, 常春晓等 (1678)
重组人促黄体激素释放激素 - 绿脓杆菌外毒素 A 融合蛋白 I 期人体耐受性临床研究	周爱萍, 杜春霞, 刘鹏等 (1683)
复方苦参注射液联合化疗治疗中晚期恶性肿瘤的疗效观察	韦爱芳, 张发恩, 蓝川等 (1688)
复方苦参注射液对鼻咽鳞癌患者外周血中 cyclinB2 的影响	王建功, 王晓红, 胡万宁等 (1691)
新辅助化疗对大肠癌患者 CD44v6, p27 蛋白表达与预后的影响	孙秀梅, 高峰, 李贵新等 (1695)
复方苦参注射液防治放射性口炎的临床研究	郝建清 (1699)
复方苦参注射液治疗胃肠癌术后化疗患者 58 例	林恒军, 付宝娟, 楼立新 (1701)

■ 实验研究

微管抑制剂 C9 抑制新生血管生成的作用机制	任莹, 林莉萍, 丁健 (1703)
(5- 氟脲嘧啶 -1- 乙酸) -4' - 姜黄素酯的合成及抗肿瘤活性	吴敏, 刘洋, 魏晓霞等 (1711)
铂类抗肿瘤药物米铂的合成及结构表征	王庆琨, 普绍平, 栾春芳等 (1715)
环磷酰胺衍生物 SLXM-2 对小鼠脑瘤 B ₂₂ 的抗肿瘤作用及机制	钟帼, 徐波, 郭维等 (1718)

■ 不良反应

左旋门冬酰胺酶不良反应引起的儿童用药安全性问题	黄琳, 刘一, 任晓蕾等 (1723)
-------------------------------	---------------------

CHINESE JOURNAL OF NEW DRUGS

Semimonthly

Volume 20, Number 17,

September 15, 2011

CONTENTS



- Further improving research quality in cancer management by integration of traditional Chinese medicine and modern medicine.....SUN Yan (1589)
- Targeted therapy for non-small-cell lung cancer using EGFR-TKIs
.....TAN Fen-lai, WANG Yin-xiang, YUAN Xiao-fen, *et al* (1594)
- Pharmacological effects and clinical research of the new drug crizotinib for treating lung cancer
.....WANG Yan, YU Shu-fei (1602)
- Consideration of exposure-response relationships during clinical trials of new drugs
.....WEI Min-ji, ZHAO Ming, SHAN Ai-lian (1608)
- Comparison of Chinese clinical trial regulation system with relevant international law
.....YAN Yong-bo, LI Ye (1612)
- Application status of small molecule targeted anti-cancer drugs in China
.....CHEN Xiao-yuan, ZHANG Hong, GAO Cheng-yan, *et al* (1615)
- Progress in the study of T cell-dependent antibody response
.....HUO Yan, AI Wen-chao, Miao Yu-fa, *et al* (1620)
- Central composite design optimizes preparation of norcantharidin-loaded chitosan-fibroin microspheres for embolization.....ZHANG Guang-yu, CHI Mei-yu, NI Jing, *et al* (1624)
- Preparation of lactosyl-norcantharitin phospholipid complex and its pH-sensitive liposomes
.....ZHOU Yi, XU Jing-yu, GUAN Min, *et al* (1631)
- Traditional chinese medicine and cancer: historic deposits and 50-years innovation and development
.....LIN Hong-sheng, ZHANG Ying (1639)
- Interpretation of drugs for advanced non-small cell lung cancer in 2011.....XING Pu-yuan, SHI Yuan-kai (1643)
- Interpretation of the principles of pharmacotherapy in Chinese Guideline for Renal Cell Carcinoma 2011
.....SHOU Jian-zhong, MA Jian-hui (1647)
- Impact of early intervention on chronic CML patients with imatinib failure and the selection of second-generation TKIs.....ZHOU Li (1652)
- Progress in imatinib adjuvant therapy of gastrointestinal stromal tumor.....JIANG Wei-zhong (1657)
- Current status of research and development of new tyrosine kinase inhibitors
.....ZHOU Bing-ying, AN Chun-na, PU Xiao-ping (1661)
- Advance in research of cyclin-dependent kinase 2 inhibitors based on the structures of target proteins
.....BAI Xiao-guang, XU Le-xing, LI Yi-liang, *et al* (1667)
- A perspective, open-label, and multi-center phase II study of FOLFOX 4 regimen as systemic therapy for patients with unresectable hepatocellular carcinoma.....GONG Xin-lei, QIN Shu-kui, WANG Ya-jie, *et al* (1673)
- Tolerability of famitinib malate: the preliminary results from phase I clinical trial
.....ZHOU Ai-ping, ZHANG Wen, CHANG Chun-xiao, *et al* (1678)

Phase I clinical trial of lyophilized recombinant human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion protein.....ZHOU Ai-ping, DU Chun-xia, LIU Peng, *et al* (1683)

Efficacy of composite matrine injection combined with chemotherapy in the treatment of advanced cancerWEI Ai-fang, ZHANG Fa-en, LAN Chuan, *et al* (1688)

Effect of composite matrine injection on cyclinB2 in blood of patients with advanced nasopharyngeal squamous cell carcinoma.....WANG Jian-gong, WANG Xiao-hong, HU Wan-ning, *et al* (1691)

Influence of new neoadjuvant chemotherapy on the prognosis and the protein expression of CD44v6 and p27 in patients with colorectal carcinoma.....SUN Xiu-mei, GAO Feng, LI Gui-xin, *et al* (1695)

Efficacy of compound radix sophorae flavescentis injection in the prevention of radiation stomatitisHAO Jian-qing (1699)

Effect of matrine injection in 58 gastrointestinal cancer patients with postoperative chemotherapyLIN Heng-jun, FU Bao-juan, LOU Li-xin (1701)

Mechanism underlying the anti-angiogenic effect of the novel tubulin inhibitor C9REN Xuan, LIN Li-ping, DING Jian (1703)

Synthesis and anti-tumor effect of (5-fluorouracil-1-acetic acid)-4'-curcuminatWU Min, LIU Yang, WEI Xiao-xia, *et al* (1711)

Synthesis and structural characterization of miriplatin, a platinum-based anti-tumor drugWANG Qing-kun, PU Shao-ping, LUAN Chun-fang, *et al* (1715)

Antitumor effect and mechanism of the cyclophosphamide derivative SLXM-2 on B₂₂ brain tumor in miceZHONG Guo, XU Bo, GUO Wei, *et al* (1718)

Safety considerations in children: L-asparaginase-induced adverse drug reactionsHUANG Lin, LIU Yi, REN Xiao-lei, *et al* (1723)

Directed by : State Food and Drug Administration
Sponsored by : China Medico-Pharmaceutical Science and Technology Publishing House
 China National Pharmaceutical Group Corp.
 Chinese Pharmaceutical Association

Editor-in-Chief : SANG Guo-wei
Board Chairman/General Manager : SONG Rui-lin
Director : SONG Rui-lin WU Shao-zhen
 LI Shao-li DENG Jin-dong ZHU Jing-jin

General Manager : FENG Lan
Deputy General Manager : WANG Zhe
Editorial Department Director : HAN Pei
Editor and Publisher : Chinese Journal of New Drugs Co., Ltd.
Address : Floor 8, Luyang Building, No.6 Beisanhuanzhonglu
 Xicheng District, Beijing 100120, China
 Tel: (010)82282302 / 82282300 / 82282301 / 82282329 / (010)82282326
 Fax: (010)82282289

Http://www.newdrug.cn
E-mail : cndj2009@gmail.com / cndj@newdrug.cn

Printer : Military Headquarter's Printery of Beijing
Domestic Distribution : Beijing Post Offices
Overseas Distribution :
 China International Book Trading Corp.
 (P.O.Box 399 Beijing, China)
Domestic Subscription : Local Post Offices
Periodical Registration :
 ISSN 1003-3734 CN 11-2850/R
Publication Date : September 15, 2011
Copyright :
 2011 by Chinese Journal of New Drugs Co.,Ltd

[期刊基本参数]

CN 11-2850 / R*1992*sm*A4*140*zh*P*Y 12.00**30*2011-17

责任编辑 杨青 英文审校 魏尔清 杜小莉